Viking Finalizes $500M Upsized Offering: 7.86M Shares at $35.00 Plus $225M Convertible Notes
VKTX sits 49% above its 52-week low of $24.78 on elevated volume (8.5× avg).
Summary
Viking Therapeutics finalized its upsized $500 million concurrent offering: 7.86 million common shares at $35.00 and $225 million in 2.00% convertible notes due 2032, with net proceeds of approximately $476 million to fund VK2735 and VK3019 development.
Updates
· SEC 8-K — Net proceeds were approximately $297.0 million from the equity offering and $250.8 million from the debt offering, totaling about $547.8 million.
· PR Newswire — The offering closed with full underwriter option exercise, bringing gross proceeds to approximately $575.0 million and net proceeds to approximately $547.8 million.
· SEC 424B5 — The notes offering includes a 30-day underwriters' option to purchase up to an additional $33.75 million principal amount to cover over-allotments.
Key Events · Financing and Capital Events · VKTX
-
Upsized $500M Concurrent Offering Finalized
7,857,143 common shares priced at $35.00 per share for $275 million gross proceeds, plus $225 million in 2.00% convertible senior notes due 2032 — up from the originally announced $400 million.
-
Convertible Note Terms Set
Notes carry a 2.00% coupon, mature October 15, 2032, and convert at 19.7044 shares per $1,000 principal amount — an initial conversion price of approximately $50.75 per share, about 37% above today's $36.98 price.
-
Net Proceeds and Use of Funds
Estimated net proceeds of $258.2 million from common stock and $218.0 million from notes (before over-allotments) will fund VK2735 clinical development, VK3019 advancement, and general corporate purposes.
-
Dilution Impact
Common stock tranche adds approximately 6.7% to shares outstanding; investors in the offering face immediate dilution of $29.35 per share based on pro forma net tangible book value of $5.65 per share.
Analysis · VKTX · Life Sciences
Viking Therapeutics locked in the terms of its upsized $500 million concurrent capital raise, pricing 7,857,143 common shares at $35.00 each for $275 million in gross proceeds alongside $225 million in 2.00% convertible senior notes due 2032. The common stock tranche alone adds roughly 6.7% to the share count, and the convertible notes carry an initial conversion price of approximately $50.75 per share — about 37% above today's $36.98 price — meaning meaningful additional dilution if the stock recovers. The deal was upsized from the originally announced $400 million, reflecting strong institutional demand following the positive Phase 2 maintenance data for VK2735 announced September 22. Proceeds of approximately $476 million combined (before over-allotments) extend the cash runway for the VK2735 Phase 3 program and VK3019 development, but existing shareholders absorb immediate dilution at a price below the $40.85 last reported sale on September 22.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.7% of the 1024 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $36.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $24.78 to $43.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.